Scarica l'app Stockscreener
11.55
0.70%
0.08
Dopo l'orario di chiusura:
11.31
-0.24
-2.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.47
Aprire:
$11.58
Volume 24 ore:
1.00M
Relative Volume:
0.52
Capitalizzazione di mercato:
$1.52B
Reddito:
$260.11M
Utile/perdita netta:
$60.64M
Rapporto P/E:
26.86
EPS:
0.43
Flusso di cassa netto:
$92.29M
1 W Prestazione:
-0.60%
1M Prestazione:
-7.75%
6M Prestazione:
+50.59%
1 anno Prestazione:
+60.86%
Intervallo 1D:
$11.44
$11.72
Intervallo di 1 settimana:
$10.90
$11.72
Portata 52W:
$6.55
$13.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Confronta AUPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
11.55 | 1.48B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Working capital per share of Aurinia Pharmaceuticals Inc. – LS:A1W7D4 - TradingView
Combining price and volume data for Aurinia Pharmaceuticals Inc.Trade Performance Summary & Precise Swing Trade Alerts - newser.com
Aurinia to present new voclosporin data at rheumatology conferences By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals Experiences Revision in Score Amid Strong Financial Metrics and Market Position - Markets Mojo
Is Aurinia Pharmaceuticals Inc a good long term investmentSector Performance Review & Free Unmatched Market Gains - earlytimes.in
How to escape a deep drawdown in Aurinia Pharmaceuticals Inc.2025 Trade Ideas & Reliable Intraday Trade Plans - newser.com
Aurinia to present new Lupkynis® data at ACR Convergence and ASN Kidney Week 2025 - MarketScreener
Aurinia to Present New LUPKYNIS® Data at ACR Convergence and ASN Kidney Week 2025 - TradingView
Aurinia Pharmaceuticals Inc. Announces Upcoming Presentations of New Data on LUPKYNIS®? at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - MarketScreener
at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - Business Wire
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - The Joplin Globe
Can Aurinia Pharmaceuticals Inc. stock reach $100 price targetGap Up & Community Verified Trade Signals - newser.com
Aurinia Pharmaceuticals Inc (IKAP.SG) stock price, news, quote and history - Yahoo
Does Aurinia’s Latest Share Spike Reflect Its True Value After Recent Pipeline Updates? - Yahoo Finance
Can Aurinia Pharmaceuticals Inc. (IKAP) stock reach $200 price targetTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Statistical indicators supporting Aurinia Pharmaceuticals Inc.’s strengthTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Technical analysis overview for Aurinia Pharmaceuticals Inc. stockTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Real time breakdown of Aurinia Pharmaceuticals Inc. stock performance2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
What the charts say about Aurinia Pharmaceuticals Inc. todayRate Hike & Daily Stock Trend Reports - newser.com
Market reaction to Aurinia Pharmaceuticals Inc.’s recent newsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Predicting Aurinia Pharmaceuticals Inc. trend using moving averages2025 Geopolitical Influence & Weekly High Momentum Picks - newser.com
Aurinia Pharmaceuticals' (AUPH) "Hold (C)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Analyzing net buyer seller activity in Aurinia Pharmaceuticals Inc.2025 Fundamental Recap & Free Community Consensus Stock Picks - newser.com
Can trapped investors hope for a rebound in Aurinia Pharmaceuticals Inc.Weekly Profit Recap & Fast Moving Stock Trade Plans - newser.com
Combining machine learning predictions for Aurinia Pharmaceuticals Inc.Portfolio Return Report & Stock Portfolio Risk Management - newser.com
Will Aurinia Pharmaceuticals Inc. price bounce be sustainableMarket Risk Summary & Proven Capital Preservation Methods - newser.com
Is Shriram Asset Management Company Limited a Hybrid Growth Value Stock Worth HoldingPrice Gap Trading Strategies & Achieve Triple Digit Returns - earlytimes.in
Aurinia Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Aurinia Pharmaceuticals IncCommon Shares (NQ: - FinancialContent
Aurinia Pharmaceuticals Inc (AUPH) stock forecast and price target - Yahoo
How Aurinia Pharmaceuticals Inc. (IKAP) stock compares with top peers2025 Short Interest & Community Consensus Picks - newser.com
Pattern recognition hints at Aurinia Pharmaceuticals Inc. upsidePortfolio Update Report & Proven Capital Preservation Methods - newser.com
Using AI based signals to follow Aurinia Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - newser.com
Forecasting Aurinia Pharmaceuticals Inc. price range with options dataQuarterly Market Review & High Return Trade Opportunity Guides - newser.com
Could Regulatory Scrutiny Shift the Risk Profile for Aurinia Pharmaceuticals (AUPH)? - Sahm
How high can Aurinia Pharmaceuticals Inc. stock go2025 Momentum Check & High Accuracy Investment Signals - newser.com
Smart tools for monitoring Aurinia Pharmaceuticals Inc.’s price actionGap Up & Verified Stock Trade Ideas - newser.com
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Aurinia drops after FDA official criticizes voclosporin - MSN
Aurinia Pharmaceuticals Hits Day Low of $11.04 Amid Price Pressure - Markets Mojo
Aurinia responds after top FDA official’s comment on lead drug - MSN
Aurinia Sinks After FDA Official Questions Its Drug in Post - MSN
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aurinia Pharmaceuticals Inc Azioni (AUPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):